LY2828360 – 25 mg

Brand:
Cayman
CAS:
1231220-79-3
Storage:
-20
UN-No:
Non-Hazardous - /

LY2828360 is a cannabinoid (CB) receptor 2 agonist (Ki = 40.3 nM).{43815} It selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100,000 nM, respectively). It reduces differences in hind paw weight bearing between monoiodoacetic acid- and saline-injected knees in a rat model of knee joint-related chronic pain induced by monoiodoacetic acid (MIA) when administered at doses greater than or equal to 0.1 mg/kg. LY2828360 dose-dependently reduces mechanical and cold allodynia induced by paclitaxel (Item No. 10461) in mice and prevents development of morphine tolerance when administered at dose of 3 mg/kg per day for 12 days.{43816} It also reduces paclitaxel-induced allodynia in morphine-tolerant mice.  

 

Available on backorder

SKU: 26791 - 25 mg Category:

Description

A CB2 agonist (Ki = 40.3 nM) selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100,000 nM, respectively); reduces differences in hind paw weight bearing between MIA- and saline-injected knees in a rat model of knee joint-related chronic pain induced by MIA at ≥0.1 mg/kg; dose-dependently reduces paclitaxel-induced mechanical and cold allodynia in mice and prevents development of morphine tolerance at 3 mg/kg per day for 12 days; reduces paclitaxel-induced allodynia in morphine-tolerant mice


Formal name: 8-(2-chlorophenyl)-2-methyl-6-(4-methyl-1-piperazinyl)-9-(tetrahydro-2H-pyran-4-yl)-9H-purine

Synonyms: 

Molecular weight: 426.9

CAS: 1231220-79-3

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Neuroscience|Pain Research